• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MHRA Filing Acceptance Could Be A Big Step For Ultragenyx Stock (RARE)

    Simply Wall St·11/12/2026 05:21:39
    Listen to the news
    • Ultragenyx Pharmaceutical reported that the UK MHRA accepted its Marketing Authorisation Application for UX111, an investigational gene therapy for Sanfilippo syndrome Type A, following earlier EMA review initiation and prior FDA approval. This marks a regulatory review phase across multiple major regions for this ultra-rare pediatric disorder.
    • The MHRA acceptance, NICE routing of UX111 into the Highly Specialised Technology programme, and reaffirmed 2026 revenue guidance with a 2027 profitability target together highlight how Ultragenyx is trying to convert its rare disease science into a commercially durable gene therapy platform while managing cost intensity and reimbursement complexity.
    • We will now look at how Ultragenyx's efficiency-challenged investment narrative intersects with UK MHRA review progress for the UX111 gene therapy.

    Scan how Ultragenyx Pharmaceutical's rare disease focus compares with other specialised opportunities by reviewing the hand-picked list of solid balance sheet and fundamentals (23 results) in this corner of the market.

    Ultragenyx Pharmaceutical Investment Narrative Recap

    To own Ultragenyx Pharmaceutical, you need to believe that its rare disease portfolio and gene therapy platform can eventually support the cost base that, according to AnimalDoctorKwon, a Simply Wall St Community investor who wrote the Narrative, has looked structurally heavy. The reaffirmed 2026 revenue guidance of US$730 million to US$760 million and target of GAAP profitability from 2027 indicate that management is still steering toward a leaner model.

    In the short term, the focus now sits on execution around new gene therapies like UX111 and disciplined spending. The biggest risk remains large ongoing losses and less than one year of cash runway. UK and EMA review progress for UX111 are important, but do not yet change that funding and cost efficiency question.

    The most relevant backdrop to the UX111 headlines is Ultragenyx reaffirming that it aims for GAAP profitability in 2027 and beyond. Third quarter 2026 revenue of US$173 million and a net loss of US$118 million show that the commercial engine is still loss making, even with multiple approved rare disease treatments already on the market.

    AnimalDoctorKwon argues that this pattern reflects a commercial model where SG&A and manufacturing demands absorb much of the top line. UX111 and other gene therapies could add meaningful complexity and capital needs. For you as a shareholder, the operational test is whether new launches and international approvals help close the gap between revenue scale and ongoing cash burn instead of stretching it further.

    Using a discounted cash flow style framework, AnimalDoctorKwon arrives at a narrative fair value of US$26.00 per share for Ultragenyx Pharmaceutical by applying 5.9% annual revenue growth and a future profit margin of 18.0%, and then capitalising those projected cash flows into today’s price terms.

    Uncover how Ultragenyx Pharmaceutical's fair value indicates a 56% potential upside to its current price before other investors close that discount.

    NasdaqGS:RARE 1-Year Stock Price Chart
    NasdaqGS:RARE 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest analysts focus on a different risk for Ultragenyx Pharmaceutical. Payer pushback on multi million dollar gene therapies is their key worry, which could cap UX111 volumes even with MHRA review now underway. Before this news, the most bearish group was modeling about 14.1% annual revenue growth and no profitability within 3 years, which shows how far expectations can spread. These views may shift as the UK and EMA decisions progress, so it makes sense for you to compare several narratives before deciding how UX111 fits your own thesis.

    Explore 4 other Ultragenyx Pharmaceutical fair value estimates, including one that suggests it could be worth just $25.35!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.

    Looking for more Ultragenyx Pharmaceutical sized ideas?

    Once you have a handle on Ultragenyx Pharmaceutical, it can help to widen the lens and compare it with other opportunities that fit different risk and balance sheet profiles. The Simply Wall St Screener is built for exactly that kind of side by side work, so you can stress test your thesis across a broader watchlist.

    • If capital preservation sits high on your priority list, take a look at companies that score well on resilience and balance sheet strength using the 30 resilient stocks with low risk scores.
    • For investors hunting for mispriced quality, broaden your watchlist with the 32 high quality undervalued stocks that combine healthier fundamentals with potential valuation gaps.
    • If you prefer businesses that fly under most radars, scan through the 19 high quality undiscovered gems that pair stronger financial profiles with lower market attention.